The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
BACKGROUND
The COMBINE (combined pharmacotherapies and behavioral intervention) clinical trial recently evaluated the efficacy of pharmacotherapies, behavioral therapies, and their combinations for the treatment of alcohol dependence. Previously, the cost and cost-effectiveness of COMBINE have been studied. Policy makers, patients, and nonalcohol-dependent individuals may be concerned not only with alcohol treatment costs but also with the effect of alcohol interventions on broader social costs and outcomes.


OBJECTIVE
To estimate the sum of treatment costs plus the costs of health care utilization, arrests, and motor vehicle accidents for the 9 treatments in COMBINE 3 years postrandomization.


METHODS
A cost study based on a randomized controlled clinical trial.


METHODS
: The study involved 786 participants 3 years postrandomization.


RESULTS
Multivariate results show no significant differences in mean costs between any of the treatment arms as compared with medical management (MM) + placebo for the 3-year postrandomization sample. The median costs of MM + acamprosate, MM + naltrexone, MM + acamprosate + naltrexone, and MM + acamprosate + combined behavioral intervention were significantly lower than the median cost for MM + placebo.


CONCLUSIONS
The results show that social cost savings are generated relative to MM + placebo by 3 years postrandomization, and the magnitude of these cost savings is greater than the costs of the COMBINE treatment received 3 years prior. Our study suggests that several alcohol treatments may indeed lead to reduced median social costs associated with health care, arrests, and motor vehicle accidents.
Zarkin
Gary A
GA
RTI International, Research Triangle Park, NC 27709, USA. gaz@rti.org
Bray
Jeremy W
JW
Aldridge
Arnie
A
Mills
Michael
M
Cisler
Ron A
RA
Couper
David
D
McKay
James R
JR
O'Malley
Stephanie
S
D000077443:Acamprosate; D000063:Accidents, Traffic / Q000191:economics* / Q000706:statistics & numerical data; D000427:Alcohol Deterrents / Q000191:economics / Q000627:therapeutic use; D019973:Alcohol-Related Disorders / Q000191:economics* / Q000628:therapy*; D001521:Behavior Therapy / Q000191:economics; D003365:Costs and Cost Analysis; D003415:Crime / Q000191:economics* / Q000706:statistics & numerical data; D006296:Health Services / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D009271:Naltrexone / Q000191:economics / Q000627:therapeutic use; D013654:Taurine / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
D000427:Alcohol Deterrents; D013654:Taurine; D009271:Naltrexone; D000077443:Acamprosate
Addiction. 2000 Jul;95(7):999-1013
10962766
J Health Econ. 2001 Jul;20(4):461-94
11469231
J Subst Abuse Treat. 2003 Jul;25(1):51-7
14512108
Drug Alcohol Depend. 2004 Jun 11;74(3):223-34
15194200
JAMA. 2004 Mar 10;291(10):1238-45
15010446
J Stud Alcohol. 2001 Jan;62(1):89-97
11271969
J Subst Abuse. 1991;3(1):13-27
1821272
J Stud Alcohol Suppl. 2005 Jul;(15):50-5; discussion 33
16223056
JAMA. 2006 May 3;295(17):2003-17
16670409
Med Care. 2004 Apr;42(4):395-402
15076817
Prev Sci. 2006 Dec;7(4):333-42
16845591
Med Care. 2010 Apr;48(4):306-13
20355261
Arch Gen Psychiatry. 2008 Oct;65(10):1214-21
18838638
BMJ. 2005 Sep 10;331(7516):544
16150765
J Stud Alcohol. 1997 Nov;58(6):625-37
9391923
Alcohol Health Res World. 1987 Fall;12(1):8-15
10312354
J Stud Alcohol Drugs. 2007 Mar;68(2):248-55
17286343
J Stud Alcohol. 2004 Nov;65(6):758-65
15700514
J Subst Abuse Treat. 1996 Nov-Dec;13(6):453-66
9219142